4WM
NRIX icon

49 Wealth Management’s Nurix Therapeutics NRIX Stock Holding History

49 Wealth Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$155K Sell
10,018
-140
-1% -$2.32K 0.01% 192
2025
Q4 		$193K Sell
10,158
-1,520
-13% -$21.8K 0.02% 188
2025
Q3 		$108K Buy
+11,678
New +$121K 0.01% 189
2024
Q2 		– Sell
-12,503
Closed -$182K – 167
2024
Q1 		$182K Sell
12,503
-1,185
-9% -$12.7K 0.04% 118
2023
Q4 		$141K Buy
+13,688
New +$93.8K 0.04% 115

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

49 Wealth Management's NRIX Position: Q1 2026 in Review

49 Wealth Management reduced its Nurix Therapeutics (NRIX) stake by 1.4% in Q1 2026, selling an estimated $2.32K and leaving 10,018 shares worth $155K. The position accounts for 0.01% of the portfolio, ranked #192.

49 Wealth Management first reported a position in NRIX in Q4 2023 and has held it in 5 quarters since. The position peaked at $193K in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • 49 Wealth Management held 10,018 shares of Nurix Therapeutics worth $155K as of Q1 2026.
  • 49 Wealth Management sold 140 Nurix Therapeutics shares in Q1 2026, an estimated $2.32K.
  • Nurix Therapeutics made up 0.01% of 49 Wealth Management's portfolio in Q1 2026, its #192 holding.
  • 49 Wealth Management first reported a position in Nurix Therapeutics in Q4 2023 and has held it in 5 quarters since.
  • 49 Wealth Management's Nurix Therapeutics position peaked at $193K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on 49 Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.